On Sept. 1, 2020, HDT Bio received a notice of award from the National Institute of Allergy and Infectious Disease at the National Institutes of Health.

The approved contract provided $8.2M in support of pre-clinical and clinical activities to be conducted by HDT and collaborators to accelerate development of HDT-301 a COVID-19 vaccine candidate.